Objective: To evaluate the association of type and timing of prophylactic maternal and infant antiretroviral regimen with time to first positive HIV-1 DNA PCR test, in nonbreastfed HIV-infected infants, from populations infected predominantly with HIV-1 non-B subtype virus.
Introduction
To assess HIV infection in infants, serologic tests are only reliable when performed beyond 15-18 months of age because infants can carry maternal antibodies for more than a year after birth. In contrast, virologic diagnostic tests that detect the presence of HIV can be used at earlier ages. These tests include viral culture, viral antigen (p24), proviral DNA using PCR, and HIV DNA/RNA amplification and detection [1] . HIV-1 DNA or RNA amplification assays are recommended for diagnosis of HIV in infants under 15 months of age. Therefore, knowledge of the performance of these assays is essential to inform HIV diagnosis guidelines.
Previous investigations have evaluated the performance characteristics of these virologic assays for the early diagnosis of HIV infection in various individual cohorts. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . PCR assays typically achieve high specificity, and thus a positive test result is indicative of HIV infection with high probability. However, the sensitivity of PCR assays in newborns is lower in the first few weeks of life and increases thereafter. This is likely related to intrapartum transmission, which is not being detected in the newborn sample. For example, in a population of infants infected with subtype B HIV-1, Dunn et al. [18] estimate that 38% [95% confidence interval (CI) 29%, 46%] of all perinatally infected infants test positive within a day after birth. By 14 days after birth, 93% (95% CI 76%, 97%) test positive. This heterogeneity in the timing of first positive DNA PCR likely reflects the varying timing of infection (in utero vs. intrapartum) and the sensitivity of early detection of intrapartum infections (for HIV exposure at labor/delivery, actual establishment of infection with viremia, and/or viral DNA integration has not yet occurred). It is also possible that the interplay of elements such as type of antiretroviral prophylaxis regimen, maternal or infant hostmediated factors that may suppress viral replication at delivery, or the sensitivity of different diagnostic assays, may affect detection of virus in the newborn period.
No previous work provides an assessment of the association of combination antiretroviral prophylaxis regimen and/or infant prophylaxis with the time to positive signal for DNA assays. Current WHO and other guidelines for clinical management of HIV-infected pregnant women include use of combination antiretroviral regimens. [19] [20] [21] [22] [23] Conversely, current recommendations regarding the scheduling of diagnostic tests in HIV-exposed infants are based on studies conducted prior to the era of combination antiretroviral regimens [24, 25] . These prophylactic regimens, being potent suppressors of viral replication, may delay the detection of HIV infection by virus-based assays in infants. Therefore, knowledge of the performance of these assays at different infant ages according to type of prophylaxis (particularly maternal and infant combination antiretroviral prophylaxis) is essential to inform HIV diagnosis guidelines.
Whereas several previous studies addressed the performance of HIV-1 DNA assays in HIV-infected infants infected with HIV-1 subtype B virus, relatively few studies have evaluated the performance of HIV-1 DNA assays in infants infected with non-B subtypes [1] [2] [3] 5, [10] [11] [12] [13] [14] [15] . Non-B subtypes are prevalent in regions such as subSaharan Africa and Asia, which bear the major burden of mother-to-child transmission (MTCT) of HIV. Previous studies on mother-infant pairs infected with non-B subtype HIV-1 have been limited in sample size, ranging from 38 infants in a study conducted in South Africa [16] , where subtype C HIV-1 infection is predominant, to 98 infected infants in a study conducted in Thailand [6] , where subtype E HIV-1 or CRF01_AE is most prevalent.
Studying nonbreastfed infants provides particular insight regarding the time to positive signal associated with amplification assays, as there is no continuing HIVexposure after birth via breast milk, and timing of transmission is limited to in-utero and intrapartum infection. This study presents results from the analysis of combined data on HIVinfected, nonbreastfed infants and their HIV-infected mothers from prospective studies conducted in three countries in which non-B subtype virus is prevalent.
Methods
Prospective studies of HIV-infected mothers and their nonbreastfed infants from Botswana, Thailand, and the United Kingdom were included. All these studies previously received corresponding ethics committee approvals. Because this study represents a secondary analysis of pooled, de-identified data across the aforementioned studies, the Human Subjects Research Protection offices of the lead institutions involved in the analysis (University of Massachusetts at Amherst and Harvard T. H. Chan School of Public Health) approved this study under a nonhuman-subjects-research determination. All studies provided individual data on all HIVinfected infants satisfying the following inclusion criteria: at least one HIV-1 DNA PCR result available within 3 months of birth; mothers diagnosed with HIV no later than 2 days following delivery; and infants that were replacement-fed (did not breastfeed). 
Statistical methods
Time to first positive HIV-1 DNA PCR test among all nonbreastfed HIV-infected infants was estimated using parametric models appropriate for interval-censored outcomes. The models provide estimates of the probabilities of testing positive by HIV-1 DNA PCR among HIV-infected, nonbreastfed infants, by age of infant. Time to first positive HIV-1 DNA PCR was estimated according to maternal or infant antiretroviral regimen category and timing of maternal antiretroviral initiation. These variables could not be modeled jointly due to their high concordance (Table 1) . Stratified Weibull models were fit to evaluate the association of each primary variable (maternal/infant antiretroviral regimen, timing of maternal antiretroviral initiation) with time to first positive HIV-1 DNA PCR [34] . Models were adjusted for other covariates including maternal CD4 þ cell count and viral load closest to the time of delivery, mode of delivery, gestational age, and infant birth weight. Models could not be adjusted for country because the primary variables were each confounded with country (e.g. 94.4% of the patients in the maternal cART group were from the NSHPC study, and none were from the studies in Thailand; see Table S1 in the Supplemental Digital Content, http://links.lww.com/QAD/B158). As a sensitivity analysis, analyses were repeated for the subgroup of 299 HIV-infected infants from the studies in Thailand, to assess whether the results changed when analyses were restricted to one country. Further details on the analyses are included in the Supplemental Digital Content (http://links.lww.com/QAD/B158).
Results
The dataset included 405 HIV-infected, nonbreastfed infants. Maternal antiretroviral regimen had a high degree of concordance with infant antiretroviral regimen (81%; Table 1 ). The timing of maternal antiretroviral initiation tended to be earlier in pregnancy for more complex regimens; 42% of women who received cART and 5% or less of women who initiated less complex antiretroviral regimens started prior to the trimester of delivery (Table  1) . A similar relationship between infant antiretroviral regimen and timing of maternal antiretroviral initiation was observed (data not shown).
Maternal and infant characteristics according to maternal antiretroviral regimen category are shown in Table S1 of the Supplemental Digital Content (http://links.lww.-com/QAD/B158). The maternal antiretroviral regimen groups differed significantly with respect to several characteristics: Women in the cART group were primarily from the NSHPC cohort and enrolled later, had lower CD4 þ cell counts, lower viral loads, were more often diagnosed during pregnancy, and more often had subtype C or mixed subtype than women in the other antiretroviral regimen groups.
Although each of the primary variables (maternal/infant antiretrovirals, timing of antiretroviral initiation) was significantly associated with time to first positive HIV-1 DNA PCR (P < 0.0001), none of the following maternal and infant characteristics was significant in univariate models: CD4 þ cell count closest to delivery (P ¼ 0.24), viral load closest to delivery (P ¼ 0.47), mode of delivery (P ¼ 0.62), gestational age (P ¼ 0.58), and birth weight (P ¼ 0.78).
Maternal antiretroviral regimen and time to first positive HIV-1 DNA PCR Maternal antiretroviral regimen was significantly associated with time to first positive HIV-1 DNA PCR in a univariate model (P < 0.0001). The probability of a positive HIV-1 DNA PCR test at 1 day after birth (as opposed to later) was significantly lower in the HIVinfected babies in the maternal 'no antiretroviral' group (48%; 95% CI 38-59%) when compared to HIV-infected infants in the single NRTI group (85%; 95% CI 80-90%) and the sdNVP þ ZDV group (76%; 95% CI 65-85%). The probability of a positive test at 1 day after birth in the maternal cART group was 66% (95% CI 49-81%). However, the probability of a positive test at or beyond 14 days of age did not differ significantly according to maternal antiretroviral regimen ( Table 2, Fig. 1a) . Whereas overall MTCT rates are lower in infants whose mothers received any antiretrovirals, our analyses were restricted to HIV-infected infants, so the higher probability of a positive test at 1 day after birth among HIV-infected infants whose mothers received any antiretrovirals compared with those whose mothers received no antiretrovirals may reflect the effect of antenatal and intrapartum treatment with antiretrovirals in reducing intrapartum transmissions; that is, among HIV-infected infants whose mothers received any antiretrovirals, most are in-utero infections (with positive DNA PCR at day 1 after birth) and relatively few are intrapartum infections (with negative DNA PCR at day 1 after birth), whereas among HIV-infected infants whose mothers received no antiretrovirals, both in-utero and intrapartum infections are frequent.
In a multivariable model, maternal antiretroviral regimen remained statistically significant after simultaneously adjusting for CD4 þ cell count and viral load closest to delivery, mode of delivery, gestational age, and birth weight (P < 0.0001). Results were similar when restricted to data from the studies in Thailand (Supplemental Digital Content, Table S3 , http://links.lww.com/QAD/B158). 
cART, combination antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; sdNVP, single-dose nevirapine; ZDV, zidovudine.
adjusting for potential confounders listed above (P < 0.0001). Results were similar when restricted to data from the studies in Thailand (Supplemental Digital Content, Table S3, DNA PCR in a univariate model (P < 0.0001). The probability of a positive test at 1 day after birth was significantly lower in the 'no antiretroviral' group (48%; 95% CI 38-59%) when compared to infants whose mothers initiated an antiretroviral regimen during the trimester of delivery (82%; 95% CI 77-87%) or during labor/delivery (86%; 95% CI 72-95%), and did not differ significantly when compared with infants whose mothers initiated an antiretroviral regimen prior to the trimester of delivery (57%; 95% CI 37-78%). However, the probability of a positive test at or beyond 14 days of age did not differ significantly according to timing of antiretroviral initiation ( Table 2 , Fig. 1c ). As noted above, the higher probability of a positive test at day 1 after birth among HIV-infected infants whose mothers started an antiretroviral regimen either during the antenatal period or during labor and delivery when compared with HIV-infected infants whose mothers received no antiretrovirals may reflect the effect of antenatal and intrapartum treatment with antiretrovirals in reducing intrapartum transmissions.
In a multivariable model, timing of maternal antiretroviral initiation remained statistically significant after simultaneously adjusting for CD4 þ cell count and viral load closest to delivery, mode of delivery, gestational age, and birth weight (P < 0.0001). Results were similar when restricted to data from the studies in Thailand (Supplemental Digital Content, Table S3 , http://links.lww.com/QAD/B158).
Subgroup analysis of infants testing negative at birth
The association of timing and type of maternal/infant antiretroviral regimen with time to first positive DNA PCR may be clearer if the analysis is restricted to a homogeneous subgroup of infants who likely acquired HIV infection during the intrapartum period. In a subgroup analysis of 143 infants who tested negative by DNA PCR within 1 day following birth, maternal antiretroviral regimen type was significantly associated with time to first positive HIV-1 DNA PCR in a univariate model (P ¼ 0.02; Fig. 2a ). However, this association was no longer statistically significant in a multivariable model after adjusting for maternal CD4 þ cell count and viral load closest to delivery, mode of delivery, gestational age, and birth weight (P ¼ 0.09).
The association of infant antiretroviral regimen was statistically significant in a univariate model (P ¼ 0.04; Fig. 2b) , and remained significant in a multivariable model after adjusting for maternal CD4 þ cell count and viral load closest to delivery, mode of delivery, gestational age, and birth weight (P ¼ 0.04). By 28 days after birth, the probability of a positive test was 73% (95% CI 60-85%) in the 'no antiretroviral' group (n ¼ 57), 66% (95% CI 53-77%) in the 'single NRTI' group (n ¼ 68), 68% (95% CI 44-90%) in the sdNVP þ ZDV group (n ¼ 12), and 31% (95% CI 14-61%) in the cART group (n ¼ 6) (Fig. 2b) . At 60 days after birth, similar patterns across infant antiretroviral regimen categories were observed.
The timing of maternal antiretroviral regimen was not statistically significant in univariate and multivariate models (P > 0.48).
Discussion
Maternal and infant antiretroviral regimen were both significantly associated with time to first positive HIV-1 DNA PCR, in multivariable models, after adjusting for potential confounders (P < 0.0001). The probability of a positive test at 1 day of age in the 'no antiretroviral' group was significantly lower when compared to each of the other antiretroviral groups. The timing of maternal antiretroviral initiation was also significantly associated with time to first positive HIV-1 DNA PCR even after adjustment for potential confounders (P < 0.0001). The probability of a positive test at 1 day of age was significantly lower among infants whose mothers received no antiretroviral, when compared to infants whose mothers initiated an antiretroviral regimen during the trimester of delivery or infants whose mothers initiated an antiretroviral regimen during the time of labor/delivery. However, these differences were not statistically significant when infants were tested beyond 2 weeks of age (Table 2 ). These findings may reflect the prophylactic effects of antiretrovirals in reducing the risk of intrapartum transmissions, resulting in a larger proportion of in-utero transmissions in antiretroviral-exposed infants when compared to infants not exposed to antiretrovirals [27] . An additional potential explanation for this finding could be a true increase in the sensitivity of the birth PCR for detecting in-utero infection, due to a longer period between transmission and testing (if transmission occurred prior to antiretroviral initiation). Whether and to what extent either of the above hypotheses is true cannot be determined by this analysis.
Our results for infants exposed to maternal single NRTI prophylaxis benefit from a larger sample size than in most other studies, for which small sample size might explain the variability in sensitivities found. In our study, the probability of a positive test at 1 day after birth was 85% (95% CI 80-88%) among infants whose mothers received single NRTI during pregnancy. Due to small sample sizes ranging from 11 to 24 infants, previous reports of DNA PCR test positivity rates at birth among infants exposed to single maternal NRTI in populations with subtype B infections have been variable, and ranged from 11 to 27% [3, 15] . Our findings in the subgroup of infants unexposed to antiretrovirals are similar to those reported in the literature in similarly antiretroviral-unexposed infants, infected with subtype B HIV-1. In our study, the probabilities of a positive test by HIV-1 DNA PCR among infants unexposed to antiretrovirals were 48% (95% CI 38-59%) and 80% (95% CI 74-86%) within 1 and 14 days after birth, respectively. Among antiretroviral-unexposed infants infected with subtype B HIV-1, Dunn et al. [18] . reported 38% (95% CI 29-46%) and 93% (95% CI 76-97%) testing positive by DNA PCR at 1 and 14 days after birth, respectively. Other reports among antiretroviral-unexposed infants infected with subtype B HIV-1 concur with these estimates [5, [11] [12] [13] [14] 17] .
Smaller studies of the sensitivity of DNA PCR for early infant diagnosis of HIV infection have also been conducted in populations infected with non-B subtype virus [6, 7, 16, 17, 35] . Based on 65 infected infants born to HIV-positive mothers enrolled in the French multicenter prospective cohort, Burgard et al. [17] reported that the sensitivity of DNA PCR at birth, and 1 and 3 months were 55%, 89%, and 100%, respectively. The results reported in the study by Burgard et al. [17] are consistent with the results in the 'no antiretroviral' group in our study. However, contradictory to our findings, Burgard et al. [17] reported that neither the presence nor type of maternal/infant ART was significantly associated with time to first positive HIV-1 DNA PCR at birth and at 1 month. Previous reports from two small, prospective studies conducted in South Africa were consistent with the findings of our study. In a prospective cohort of 38 infected infants exposed to at least maternal ZDV prophylaxis, sdNVP and infant ZDV, the proportions testing positive by HIV-1 DNA PCR at birth and at 4 weeks were 68% (95% CI 53-81%) and 88% (95% CI 69-96%), respectively [16] . In another South African study of 58 infected, nonbreastfed infants exposed to sdNVP, Sherman et al. [35] reported that the proportion of HIV-infected infants testing positive by HIV-1 DNA PCR at 6 weeks of age was 99%. Data from two previously reported studies conducted in Thailand have been included in our analysis [6, 7] .
Our study evaluated the association between timing and type of maternal/infant antiretroviral regimen and time to first positive HIV-1 DNA PCR, in the subgroup of 143 HIV-infected nonbreastfed infants who tested DNA PCRnegative within 1 day of birth. In this subgroup of infants, all HIV transmissions are likely to have occurred during the intrapartum period. Both maternal and infant antiretroviral regimen had statistically significant associations with time to first positive HIV-1 DNA PCR in univariate models (P ¼ 0.02 and 0.04); the association remained significant in multivariable models for infant antiretroviral regimens, but not maternal antiretroviral regimens (P ¼ 0.09 and 0.04).
In this subgroup, a longer time to detection of infection by HIV-1 DNA PCR was observed among infants who received cART when compared to infants who received either no antiretroviral or single NRTI. Although the sample size in the infant cART group is limited (n ¼ 6), these results are consistent with the hypothesis that the lag time between infection and DNA PCR test positivity may be prolonged among infants exposed to highly potent combination antiretroviral regimens when compared to infants unexposed to antiretrovirals or those exposed to only monotherapy regimens. These observations may lend support to testing paradigms with more repeat and/or delayed repeat testing among HIV-exposed infants who test negative at birth and are exposed to potent antiretroviral regimens. Although our analyses were restricted to data from nonbreastfed infants so that all infants had a known time of cessation of exposure to maternal HIV-1 infection, these results equally apply to breastfed infants, suggesting that HIV-diagnostic testing scheduled immediately after the end of breastfeeding may be subject to an increased rate of false-negatives among infants exposed to cART when compared to infants exposed to less potent antiretroviral regimens. Larger studies of the effects of potent antiretroviral regimens on timing of DNA PCR test positivity are needed.
When infection with nonsubtype B or group O HIV is considered a possibility, it is recommended that both HIV DNA and RNA assays should be performed on infant samples for diagnostic purposes -preferably using DNA and RNA assays that can pick up non-clade B or 0 subtypes [21] . Whereas HIV DNA PCR assays are not as sensitive as HIV RNA assays at detecting nonsubtype B or group O HIV and may have underestimated such infections, HIV RNA assays may be less sensitive than HIV DNA PCR in detecting HIV in the presence of combination antiretroviral drugs [21] . HIV DNA PCR testing was the preferred HIV testing method technology among infants in this study. The most recent WHO infant HIV-diagnostic recommendations acknowledge that DNA PCR is currently the standard method for diagnosis of HIV infection in infants [36] . Therefore, although the universe of HIV-infected infants in this study may have been underestimated based on our testing methodology, among those who were found to be HIV-infected, HIV DNA PCR testing may have increased the likelihood of detection of HIV infection among infants on cART and the sensitivity of our overall analysis in comparing various perinatal prophylaxis regimens. Therefore, despite a lack of use of RNA testing in this study, we feel that this study provides pertinent results from the point of view of common practice and in more accurately estimating the effect of combination perinatal antiretroviral prophylaxis compared to that of noncombination antiretroviral prophylaxis or no antiretroviral prophylaxis.
Limitations of this analysis include the small number of cART-exposed infants, varying sample collection and handling procedures across studies, and different DNA PCR tests used. Although the analyses were adjusted for potential confounders, there might be residual confounding by study (and by HIV subtype). To address this issue, we repeated the analyses for the subgroup of infants from the studies in Thailand and observed similar trends as in the main analysis (see Tables S2 and S3 in the Supplemental Digital Content, http://links.lww.com/ QAD/B158). Lastly, breastfeeding status was assessed by self-report; however, the possibility of unreported breastfeeding cannot be ruled out definitively.
Earlier testing for all HIV-exposed infants is clearly desirable, as it has been shown that early treatment of infected infants has a significant effect in reducing morbidity and mortality [37, 38] . However, the (very) low rate of HIV transmission with potent antiretroviral prophylaxis might suggest that early testing has limited yield and so repeat testing of almost all infants would be needed [39] . A delayed or additional later repeat testing schedule might be especially important among infants exposed to cART regimens, due to the potent effects of cART regimens on suppressing viral replication. Alternate approaches involving the use of sensitive assays and larger amounts of DNA should increase diagnosis of HIV infection at birth [40] . As the sample size in the cART group was limited in this study, future work evaluating the effects of cART regimens on DNA PCR test positivity in a larger dataset is warranted. Studies among breastfed infants are also crucial in determining the optimal scheduling of testing to facilitate early infant diagnosis of HIV infection [41] .
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